Advanced search
Start date
(Reference retrieved automatically from Web of Science through information on FAPESP grant and its corresponding number as mentioned in the publication by the authors.)

Baseline and Kinetic Circulating Tumor Cell Counts Are Prognostic Factors in a Prospective Study of Metastatic Colorectal Cancer

Full text
Souza e Silva, Virgilio [1] ; Abdallah, Emne Ali [2] ; Carvalho de Brito, Angelo Borsarelli [1] ; Braun, Alexcia Camila [2] ; Tariki, Milena Shizue [1] ; Lopes de Mello, Celso Abdon [1] ; Calsavara, Vinicius Fernando [2] ; Riechelmann, Rachel [1] ; Domingos Chinen, Ludmilla Thome [2]
Total Authors: 9
[1] AC Camargo Canc Ctr, Dept Med Oncol, BR-01509900 Sao Paulo - Brazil
[2] AC Camargo Canc Ctr, Int Res Ctr, BR-01508010 Sao Paulo - Brazil
Total Affiliations: 2
Document type: Journal article
Source: DIAGNOSTICS; v. 11, n. 3 MAR 2021.
Web of Science Citations: 0

The discovery of predictive biomarkers in metastatic colorectal cancer (mCRC) is essential to improve clinical outcomes. Recent data suggest a potential role of circulating tumor cells (CTCs) as prognostic indicators. We conducted a follow-on analysis from a prospective study of consecutive patients with mCRC. CTC analysis was conducted at two timepoints: baseline (CTC1; before starting chemotherapy), and two months after starting treatment (CTC2). CTC isolation/quantification were completed by ISET(R) (Rarecells, France). CTC expressions of drug resistance-associated proteins were evaluated. Progression-free survival (PFS) and overall survival (OS) were estimated by the Kaplan-Meier method. Seventy-five patients were enrolled from May 2012 to May 2014. A CTC1 cut-off of >1.5 CTCs/mL was associated with an inferior median OS compared to lower values. A difference of CTC2-CTC1 > 5.5 CTCs/mL was associated with a reduced median PFS. By multivariate analysis, CTC1 > 1.5 CTCs/mL was an independent prognostic factor for worse OS. Multi-drug resistance protein-1 (MRP-1) expression was associated with poor median OS. CTC baseline counts, kinetics, and MRP-1 expression were predictive of clinical outcomes. Larger studies are warranted to explore the potential clinical benefit of treating mCRC patients with targeted therapeutic regimens guided by CTC findings. (AU)

FAPESP's process: 12/01273-8 - Detection of circulating tumor cells and their correlation with tumor clinical evolution
Grantee:Fernando Augusto Soares
Support Opportunities: Regular Research Grants